TPS monitoring in metastatic breast cancer

International Journal of Biological Markers

Volumn 14, Issue 1, 1999, Pages 45-48

  Van Dalen, A ^a  

^a Institute of Tumor Marker Oncology   (Netherlands)

Author keywords

Breast cancer; Cytokevatins; Monitoring; TPS

Indexed keywords

ANTIBODY; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS;

EID: 0032942447     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400109     Document Type: Conference Paper

References (21)

1. Lamerz R, Leonhardt A, Ehrhardt H, von Lieven H. Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev Biol Med 1980; 1: 123-35.
2. Gion M. Serum markers in breast cancer management. The Breast 1992; 1: 173-8.
3. Geraghty JG, Coveney EC, Sherry F, O'Higgins NJ, Duffy MJ. CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 2831-4.
4. Molina R, Zanon G, Fillela X, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-8.
5. Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-14.
6. van Dalen A. TPS in breast cancer-A comparative study with carcinoembryonic antigen and CA 15-3. Tumor Biol 1992; 13: 10-7.
7. van Dalen A, van der Linde DL, Heering KJ, Blusse van OudAlblas A. How can treatment response be measured in breast cancer patients? Anticancer Res 1993; 13: 1901-4.
8. Schuurman JJ, Bong SB, Einarsson R. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 1996; 16: 2169-72.
9. Blijlevens NMA, Oosterhuis WP, Oosten HR, Mulder NH. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res 1995; 15: 2711-6.
10. Haywoardt JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
11. Ng JSY, Sturgeon CM, Seth J, Paterson GM, Roulston JE, Leonard RCF. Serological markers for metastatic breast cancer. Dis Markers 1993; 11: 217-23.
12. Nicolini A, Ferdeghini M, Colizzi C. Evaluation of CEA, TPA, CA 15-3, CA 549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 1993; 37: 126-33.
13. Giai M, Roagna R, Ponzone R et al. TPS and CA 15-3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res 1996; 16: 875-82.
14. Barak V, Nisman B, Roisman I et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J Tumor Marker Oncol 1997; 12: 17-25.
15. van Dalen A, Heering KJ, Barak V, et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. The Breast 1996; 5: 82-8.
16. van Dalen A, Barak V, Cremaschi A et al. The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 1998; 13: 10-5.
17. Stigbrand T, Andres C, Bellanger L, et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The ISOBM TD5-1 workshop. Tumor Biol 1998; 19: 132-52.
18. Special article: Clinical practice guidelines for the use of tumor markers in breast cancer and colorectal cancer. J Clin Oncol 1996; 10: 2843-77.
19. Bonfrer JMG. Working Group on Tumor Marker Criteria (WGTMC). Tumor Biol 1990; 11: 278-88.
20. van Dalen A. Quality control and standardization of tumor marker tests. Tumor Biol 1993; 14: 131-5.
21. van Dalen A. Analytical requirements and standardization of CA 15-3. Scand J Clin Lab Invest 1995; 55 (Suppl 221): 102-4.